This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
J-DOIT3 was a randomized, parallel-group, unmasked treatment study enrolling 2542 participants with type 2 diabetes and cardiovascular disease as a condition of interest. The registered primary endpoint was the occurrence of major cardiovascular and cerebrovascular events or death, assessed every 12 months and at the end of the study.
| Feature | J-DOIT3 |
|---|---|
| Study acronym | J-DOIT3 |
| NCT identifier | NCT00300976 |
| Phase | NA |
| Status | UNKNOWN |
| Conditions | Cardiovascular Diseases; Diabetes Mellitus, Type 2 |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Enrollment | 2542 |
| Number of arms | 2 |
| Lead sponsor | Japan Foundation for the Promotion of International Medical Research Cooperation |
| Sponsor type | Other |
2. Clinical Question
The central statistical question is whether a randomized treatment strategy centered on lifestyle consultation for weight control, diet, and exercise affects the occurrence of major cardiovascular and cerebrovascular clinical events or death in the study population.
Population
The registry identifies cardiovascular diseases and type 2 diabetes mellitus as the study conditions.
Intervention
Lifestyle consultation addressing weight control, diet, and exercise.
Comparator
The registry lists the same lifestyle-consultation description for both arms. It does not distinguish the two arm descriptions in the available intervention field.
Primary question
Does the randomized treatment strategy affect the occurrence of the registered composite cardiovascular endpoint or death?
3. Trial Design
Participants were allocated in a randomized study design.
The registry identifies a two-arm parallel design rather than a crossover or factorial structure.
The registry identifies the study as unmasked.
The registered primary purpose is treatment.
Intervention descriptions
Lifestyle consultation
- Weight control
- Diet
- Exercise
- Behavioral intervention
Lifestyle consultation
- Weight control
- Diet
- Exercise
- Behavioral intervention
4. Endpoints
The ClinicalTrials.gov record identifies one registered primary endpoint. Its wording is reproduced below because the exact event definition determines the statistical estimand.
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Primary endpoint | The occurrence of myocardial infarction, coronary bypass surgery, percutaneous transluminal coronary angioplasty, stroke, carotid endarterectomy, percutaneous transluminal cerebral angioplasty, carotid artery stenting, or death | Every 12 months, at the end of the study. |
Why the endpoint definition matters
This is a composite endpoint: several different clinical events contribute to the same primary outcome. For a statistical analysis, the first qualifying event is typically the key time-to-event quantity when the endpoint is treated as time to first occurrence. The components are not necessarily clinically identical, so interpretation should distinguish the overall composite from its individual components whenever component-level results are available.
The registry's stated time frame, “Every 12 months, at the end of the study,” describes the assessment schedule. It does not by itself specify whether the primary analysis used time to first event, cumulative incidence at a fixed time, recurrent-event methods, or another statistical estimand.
5. Statistical Methodology
No formal statistical analyses are posted in the ClinicalTrials.gov record. The appropriate analysis therefore begins with the structure of the registered endpoint and the randomized design.
Primary endpoint as a time-to-event outcome
For a randomized parallel-group trial in which the endpoint is the occurrence of a first qualifying cardiovascular or cerebrovascular event or death, a standard approach would be to define each participant's time from randomization to the first qualifying event. Participants without an observed event by the end of available follow-up would ordinarily be right-censored at their last known event-free assessment or another prespecified censoring time.
A treatment comparison can then be expressed using survival probabilities, a hazard ratio, a rate ratio under an appropriate event-rate model, or an absolute risk difference at a prespecified time point, depending on the prespecified analysis plan.
Kaplan-Meier estimation
Kaplan-Meier methods are commonly used to estimate the probability of remaining free of the composite event over time when observations can be right-censored. The resulting curve describes the event-free survival experience of each randomized group.
Here, di represents the number of events at time ti, while ni represents the number at risk immediately before that time.
Log-rank comparison
A stratified or unstratified log-rank test can be used to compare event-free survival between randomized groups when the estimand is a time-to-first-event comparison. The test evaluates whether the observed event-time distributions differ under the specified null hypothesis; it does not quantify the magnitude of the treatment effect by itself.
Cox proportional-hazards model
A Cox proportional-hazards model is another standard method for estimating a hazard ratio for a time-to-event endpoint. If the proportional-hazards assumption is reasonable, the hazard ratio provides a relative comparison of the instantaneous event rates between treatment groups over the analyzed follow-up.
The hazard ratio is a relative time-to-event measure. It is not the same as an absolute risk difference, a relative risk at a particular time, or the proportion of participants who experience benefit.
Composite endpoint analysis
The composite endpoint combines myocardial infarction, several coronary or cerebrovascular procedures, stroke, and death. A primary analysis of the composite can provide a single prespecified outcome, but the clinical meaning of an overall effect depends on which components contribute most events and whether the treatment effect is reasonably consistent across those components.
Competing events and death
Death is explicitly included as one of the qualifying events. When death is itself part of the composite, it is not treated as a competing event for the primary composite; it is one of the events that ends event-free follow-up. If individual nonfatal components were analyzed separately, however, death could become relevant as a competing event, depending on the estimand.
6. Planned Analysis
The registry says that the primary endpoint will be assessed every 12 months and at the end of the study. For an endpoint defined as the occurrence of any listed event or death, a typical primary analysis would compare the time from randomization to the first qualifying event between the randomized groups.
| Analytical question | Typical statistical approach | What it provides |
|---|---|---|
| How does event-free survival evolve over time? | Kaplan-Meier estimation | Estimated probability of remaining free of the composite event over follow-up |
| Do the randomized groups differ in event-time experience? | Log-rank test | A hypothesis test comparing the event-time distributions |
| What is the relative treatment effect? | Cox proportional-hazards model | Hazard ratio with a confidence interval |
| What is the absolute difference at a defined time? | Difference in survival or cumulative incidence at a prespecified time | An absolute measure that can complement a relative effect |
| Which components drive the composite? | Component-specific descriptive and time-to-event analyses | Understanding of the contribution of myocardial infarction, procedures, stroke, and death |
The absence of posted statistical analyses means that the registry record establishes the endpoint, study design, and assessment schedule but does not provide an estimated treatment effect, confidence interval, or p-value for the primary endpoint.
7. Statistical Methods Explained
Why is a time-to-event analysis useful for this endpoint?
The primary outcome is defined by the occurrence of clinical events or death, and participants may experience those events at different times. A time-to-event analysis uses both whether an event occurred and when it occurred, while allowing participants who remain event-free at their last assessment to contribute censored follow-up.
What does a hazard ratio represent?
A hazard ratio compares the estimated instantaneous event rates between two groups within a time-to-event model. For example, an HR below 1 would indicate a lower estimated instantaneous rate in the treatment group under the fitted model. It would not mean that the same percentage of participants experienced a corresponding reduction in their personal probability of an event.
Why is the composite endpoint statistically important?
A composite can increase the number of observed events by combining several clinically relevant outcomes. That can make a time-to-event comparison more informative than relying on a relatively uncommon individual event alone. The trade-off is interpretational: myocardial infarction, stroke, procedures, and death are different outcomes, so the overall composite should not automatically be interpreted as though all components have identical clinical importance.
What does the Kaplan-Meier curve show?
A Kaplan-Meier curve estimates the probability of remaining free from the defined event over time. A vertical difference between curves at a particular time can be translated into an absolute event-free survival difference, while the entire curve contains information about the timing of events throughout follow-up.
Why is the p-value not an effect size?
A p-value addresses evidence against a specified null hypothesis under the statistical model. It does not tell the reader how large or clinically important an effect is. A complete analysis should therefore pair hypothesis testing with an effect estimate and its confidence interval, together with absolute event probabilities at clinically meaningful times when appropriate.
Why does censoring matter?
Right-censoring allows participants without a recorded primary event during available follow-up to contribute information up to the point at which their event-free status is last known. Standard survival methods rely on assumptions about the censoring mechanism. Informative loss to follow-up can bias the estimated event-free survival if those assumptions are not reasonable.
Why should the composite's components also be examined?
An overall composite effect can be driven disproportionately by one component. Component-specific analyses help show whether the observed pattern is distributed across myocardial infarction, coronary procedures, cerebrovascular procedures, stroke, and death, although those analyses generally have fewer events and therefore greater statistical uncertainty than the composite.
8. Randomization and Causal Interpretation
Randomization is central to the causal interpretation of a comparison between the two study groups. If randomization is successfully implemented and the prespecified analysis is followed, systematic baseline differences in measured and unmeasured factors are expected to be balanced on average between treatment assignments.
What randomization provides
It creates the basis for comparing outcomes according to assigned treatment rather than relying solely on observational adjustment.
What randomization does not guarantee
It does not make the groups numerically identical on every baseline characteristic, nor does it eliminate every source of bias after follow-up begins.
Unmasked design
The registry identifies the study as having no masking. Awareness of treatment assignment can potentially affect behavior, follow-up, reporting, or other aspects of outcome ascertainment depending on the endpoint.
Composite outcome
The primary endpoint combines several clinical events and death, so the causal interpretation applies to the prespecified composite rather than automatically to every individual component.
9. Follow-Up Structure
Study start
The registry records May 2006 as the study start date.
Randomized parallel-group study
The study is registered as randomized, parallel, unmasked, and treatment-focused, with 2 arms and enrollment of 2542 participants.
Primary endpoint assessment
The occurrence of the registered cardiovascular, cerebrovascular, procedural, or mortality endpoint is assessed every 12 months.
Primary completion
The registry records March 2016 as the primary completion date.
10. Missing Statistical Elements in the Registry Record
The ClinicalTrials.gov record identifies the study design and primary endpoint but does not post statistical analyses for that endpoint. Consequently, the registry record does not provide an estimated treatment effect, confidence interval, p-value, event count, or survival curve for the primary endpoint.
| Statistical element | Registry record |
|---|---|
| Primary endpoint definition | Reported |
| Primary endpoint time frame | Reported: every 12 months, at the end of the study |
| Randomized allocation | Reported |
| Parallel design | Reported |
| Masking | Reported as none |
| Enrollment | Reported: 2542 |
| Posted statistical analyses | None |
| Primary endpoint effect estimate | Not reported in the ClinicalTrials.gov record |
| Confidence interval | Not reported in the ClinicalTrials.gov record |
| P-value | Not reported in the ClinicalTrials.gov record |
This distinction is important for statistical interpretation. The design establishes how a treatment comparison could be evaluated, but without a posted estimate and its uncertainty, there is no numerical treatment effect to interpret from the registry record.
11. Limitations
- No posted statistical analyses: the ClinicalTrials.gov record does not provide an effect estimate, confidence interval, or p-value for the registered primary endpoint.
- Arm descriptions: the registry lists the same lifestyle-consultation description for both arms, so the available record does not distinguish the arm-specific intervention strategies beyond their randomized two-arm structure.
- Composite endpoint: myocardial infarction, coronary procedures, cerebrovascular procedures, stroke, and death represent different clinical events. A composite result would require component-level context for complete interpretation.
- Assessment schedule: the endpoint is specified as being assessed every 12 months and at the end of the study, but the registry excerpt does not specify the statistical handling of events occurring between formal assessment points.
- Censoring: a time-to-event analysis would require prespecified rules for censoring and follow-up, but those rules are not reported in the available registry information.
- Analysis estimand: the registry does not specify whether the primary analysis is intended to use a time-to-first-event estimand, fixed-time risk, recurrent-event methodology, or another framework.
- Multiplicity: no multiplicity strategy for additional endpoints or analyses is specified in the available registry information.
- Subgroups: no subgroup analysis plan or subgroup results are reported in the registry information presented here.
- Missing data: no missing-data or imputation strategy is reported.
- Stratification: no randomization stratification factors are reported in the available registry information.
- Interim analysis: no interim-analysis plan is reported in the available registry information.
- Non-inferiority: no non-inferiority margin or non-inferiority framework is identified.
- Bayesian methods: no Bayesian analysis is identified in the available registry information.
12. Why This Trial Matters Statistically
J-DOIT3 is a useful statistical case study because its registered primary endpoint combines several clinically important cardiovascular and cerebrovascular outcomes with death within a randomized parallel-group design. That structure illustrates why the definition of the estimand matters as much as the choice of statistical test.
| Concept | How it appears in J-DOIT3 |
|---|---|
| Randomization | The study is registered as randomized. |
| Parallel-group design | The registry identifies 2 arms in a parallel design. |
| Unmasked treatment | The registry identifies no masking. |
| Composite endpoint | The primary outcome combines myocardial infarction, coronary procedures, cerebrovascular procedures, stroke, and death. |
| Time-to-event analysis | A natural statistical framework for an endpoint defined by the occurrence of clinical events over follow-up. |
| Kaplan-Meier estimation | Can describe event-free survival when time-to-first-event is the estimand. |
| Hazard ratio | Can provide a relative comparison of event rates under a Cox model. |
| Absolute risk | Event-free survival or cumulative event probability at a prespecified time can complement relative measures. |
| Component analysis | Separate examination of the composite components can clarify what drives the overall endpoint. |
| Censoring | Participants without a recorded event during available follow-up require appropriate handling in time-to-event methods. |
13. Composite Endpoints: The Central Statistical Issue
The primary endpoint is not a single event. It is a union of several outcomes: myocardial infarction, coronary bypass surgery, percutaneous transluminal coronary angioplasty, stroke, carotid endarterectomy, percutaneous transluminal cerebral angioplasty, carotid artery stenting, or death.
When a time-to-first-event estimand is used, the earliest qualifying event determines the participant's event time.
This structure creates several important statistical questions. First, how frequent is each component? Second, do the components have similar clinical importance? Third, are treatment effects reasonably consistent across components? Fourth, how should participants who experience one component and later experience another be handled?
Those questions cannot be answered by the composite endpoint definition alone. They require the component-level event data and the prespecified statistical analysis plan.
14. Relative Effects and Absolute Effects
A complete analysis of a cardiovascular composite would normally present both relative and absolute measures. A hazard ratio can summarize the relative difference in event rates over time, while an absolute event probability at a clinically meaningful time gives a more direct description of the event burden.
Relative measure
A hazard ratio compares instantaneous event rates under a time-to-event model. It is useful for describing the relative treatment effect but does not directly provide an absolute probability of an event.
Absolute measure
An event probability or event-free survival estimate at a prespecified time directly describes the proportion expected to remain free of the endpoint at that time under the analysis.
Confidence intervals should accompany either type of effect estimate. The interval conveys statistical uncertainty around the estimated treatment effect; it does not describe the range of outcomes that individual participants will experience.
15. Statistical Interpretation of a Future Primary Result
If a formal time-to-event analysis were posted, the primary result would ideally be read in several layers rather than from a single p-value.
The hazard ratio would describe the estimated relative difference in instantaneous event rates between randomized groups under the fitted model. An HR below 1 would indicate a lower estimated event rate in the treatment group; an HR above 1 would indicate a higher estimated event rate.
The confidence interval would quantify uncertainty around the estimated hazard ratio under the specified statistical framework. A narrow interval would indicate greater precision than a wide interval, all else equal.
The p-value would address the prespecified null hypothesis. It would not measure the size of the treatment effect, the probability that the treatment is beneficial, or the probability that the null hypothesis is true.
The statistical result would need to be considered alongside absolute event probabilities, the individual components of the composite, follow-up duration, and the assumptions of the selected time-to-event model.
16. What Would Make the Primary Analysis Complete?
For readers evaluating the statistical evidence from J-DOIT3, a complete primary analysis would connect the registered endpoint to an explicit estimand and a transparent presentation of the resulting treatment effect.
| Component | Purpose |
|---|---|
| Analysis population | Defines which randomized participants contribute to the primary efficacy analysis. |
| Time origin | Defines when follow-up begins, typically randomization for a randomized treatment comparison. |
| Event definition | Specifies exactly which of the listed outcomes constitutes the primary event. |
| Censoring rule | Defines how participants without an observed event are handled. |
| Primary estimand | Defines the treatment effect being estimated. |
| Statistical model | Specifies how the randomized groups are compared. |
| Effect estimate | Quantifies the magnitude of the treatment difference. |
| Confidence interval | Describes uncertainty around the effect estimate. |
| Hypothesis test | Provides the prespecified inferential assessment of the null hypothesis. |
| Component results | Shows which individual events contribute to the composite outcome. |
17. Study Timeline
Start date
The registry records May 2006 as the study start date.
Enrollment
The study enrolled 2542 participants and used 2 randomized parallel arms.
Primary endpoint assessment
The registered composite endpoint is assessed every 12 months and at the end of the study.
Primary completion date
The registry records March 2016 as the primary completion date.
18. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The registered design supports a randomized comparison of a composite clinical endpoint. A time-to-event framework would ordinarily be appropriate if the estimand is time to first qualifying event, but the registry does not post the formal analysis or its numerical results.
Clinical interpretation
The primary endpoint combines cardiovascular, cerebrovascular, procedural, and mortality outcomes. Any eventual treatment-effect estimate would therefore describe the prespecified composite and should be interpreted alongside the individual components.
19. Key Statistical Takeaways
| Question | Answer from the registry record |
|---|---|
| What was randomized? | The study used randomized allocation in a 2-arm parallel design. |
| How large was the study? | Enrollment was 2542. |
| Was the study masked? | No. The registry identifies masking as none. |
| What was the primary endpoint? | Occurrence of myocardial infarction, coronary bypass surgery, percutaneous transluminal coronary angioplasty, stroke, carotid endarterectomy, percutaneous transluminal cerebral angioplasty, carotid artery stenting, or death. |
| When was it assessed? | Every 12 months, at the end of the study. |
| Were statistical analyses posted? | No. |
| Is a treatment-effect estimate available in the registry? | No. |
| What analysis would typically fit the endpoint? | A time-to-first-event analysis using methods such as Kaplan-Meier estimation and Cox regression, if those methods match the prespecified estimand and analysis plan. |
20. Sources
- ClinicalTrials.gov: J-DOIT3, NCT00300976.
Continue through Clinical Biostats
Explore statistical methods, clinical trial analyses, and quantitative tools for understanding randomized clinical-trial evidence.
21. Record Summary
J-DOIT3 is registered as a randomized, parallel-group, unmasked treatment study with 2542 participants and 2 arms. Its primary endpoint is a composite of myocardial infarction, coronary bypass surgery, percutaneous transluminal coronary angioplasty, stroke, carotid endarterectomy, percutaneous transluminal cerebral angioplasty, carotid artery stenting, or death, assessed every 12 months and at the end of the study.
Statistically, the key feature is the composite clinical endpoint within a randomized design. A complete time-to-event analysis would normally specify the estimand, event and censoring rules, analysis population, treatment-effect measure, confidence interval, and hypothesis test, followed by component-level examination of the composite. The ClinicalTrials.gov record does not post statistical analyses or numerical results for the registered primary endpoint.